Supernus Reports Strong Second Quarter 2026 Financial Growth

Supernus Pharmaceuticals announced a 32% revenue increase in Q2 2026, spurred by strong sales of its growth products. The company also revealed plans to merge with Indivior Pharmaceuticals, enhancing its market position.